Compare TBBK & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | RCKT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 534.2M |
| IPO Year | 2005 | N/A |
| Metric | TBBK | RCKT |
|---|---|---|
| Price | $52.15 | $4.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $69.00 | $29.65 |
| AVG Volume (30 Days) | 462.3K | ★ 2.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.69 | N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $141,147,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.90 | $97.68 |
| P/E Ratio | $10.75 | ★ N/A |
| Revenue Growth | ★ 20.85 | N/A |
| 52 Week Low | $40.51 | $2.19 |
| 52 Week High | $81.65 | $8.80 |
| Indicator | TBBK | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 46.17 |
| Support Level | $49.50 | $4.16 |
| Resistance Level | $54.82 | $4.51 |
| Average True Range (ATR) | 1.94 | 0.34 |
| MACD | 0.26 | -0.11 |
| Stochastic Oscillator | 36.40 | 4.26 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.